Institutional Sign In

Go

GlaxoSmithKline Czech Republic - Shareholders' Equity Growth

GlaxoSmithKline CR`s Shareholders' Equity Growth reached -0.266 % in 2017. This is 102 % less than in the previous year.

$1.99

Buy Shareholders' Equity Growth data for GlaxoSmithKline Czech Republic.

$19.99

Buy all data for GlaxoSmithKline Czech Republic.

from $199/month

Buy annual subscriptions for all our products.

 
Company Unit 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017
Amgen Czech Republic % ... ... ... ... ...           37.5 16.7 -15.8 24.3 -11.7    
Bayer Czech Republic % ... ... ...               -6.69 -37.1 -1.31 -15.1 1.44    
GlaxoSmithKline Czech Republic % ... ... ...               21.4 0.377 -2.06 -2.90 2.83    
Merck Czech Republic % ... ...                 28.0 28.2 9.48 11.0 19.6    
Novartis Czech Republic %                     21.3 22.7 16.5 24.2 19.6    
Pfizer Czech Republic % ... ...                 28.8 0.865 49.8 8.56 -30.5    
Roche Czech Republic % ... ... ...               4.97 3.63 12.2 -8.48 4.50   ...
Sanofi-Aventis Czech Republic % ... ... ... ...             11.6 8.56 11.4 0.186 9.16    
Servier Czech Republic % ... ... ... ... ... ... ... ... ... ... ... ... 40.9 29.1 24.6    
Walmark % ... ... ...               15.5 -69.9 73.1 4.72 -113